HC Wainwright & Co. Reiterates Buy on CalciMedica, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis reiterates a Buy rating on CalciMedica (NASDAQ:CALC) and maintains a $20 price target.

May 14, 2024 | 11:15 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. reaffirmed a Buy rating on CalciMedica, with a price target of $20, indicating a positive outlook on the stock.
Analyst ratings, especially from reputable firms like HC Wainwright & Co., can significantly influence investor sentiment and stock prices. A reiterated Buy rating and a maintained price target suggest a strong conviction in the stock's potential, likely leading to positive short-term price movement.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100